Structural variation drives enhancer hijacking via 3D genome disruption in ccRCC - Top-Institutions - MDSpire

Structural variation drives enhancer hijacking via 3D genome disruption in ccRCC

  • By

  • Yu Dong

  • Wenjiao Xia

  • Zitong Yang

  • Liangliang Ren

  • Hongru Wang

  • Yiyang Zhou

  • Qinchen Li

  • Zhi Chen

  • Zhinan Xia

  • Yichun Zheng

  • Feifan Wang

  • Ning He

  • Bing Cheng

  • Dongmei Ma

  • Wei Shao

  • Wei Guo

  • Shuwen Wang

  • Ziqiao Liu

  • Junxiao Shen

  • Yiming Qi

  • Xuke Gong

  • Juan Jin

  • Bo Xie

  • Guixin Zhu

  • Cheng Zhang

  • January 6, 2026

  • 0 min

Share

Top Institutions in Oncology

Brief introduction explaining scope and methodology.

  • #1

    Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer Center

    New York, NY

    Key Differentiators

    • Oncology
    • Genomic Medicine
    • Urology

  • #2

    Dana-Farber Cancer Institute
    Dana-Farber Cancer Institute

    Boston, MA

    Key Differentiators

    • Oncology
    • Genomics
    • Molecular Biology

  • #3

    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center
    University of California, San Francisco (UCSF) Helen Diller Family Comprehensive Cancer Center

    San Francisco, CA

    Key Differentiators

    • Oncology
    • Genomics
    • Urology

  • #4

    MD Anderson Cancer Center
    MD Anderson Cancer Center

    Houston, TX

    Key Differentiators

    • Oncology
    • Genomic Medicine
    • Urology

  • #5

    Broad Institute of MIT and Harvard
    Broad Institute of MIT and Harvard

    Cambridge, MA

    Key Differentiators

    • Genomics
    • Cancer Biology
    • Bioinformatics

Original Source(s)

Structural variation drives enhancer hijacking via 3D genome disruption in ccRCC

  • by Yu Dong, Wenjiao Xia, Zitong Yang, Liangliang Ren, Hongru Wang, Yiyang Zhou, Qinchen Li, Zhi Chen, Zhinan Xia, Yichun Zheng, Feifan Wang, Ning He, Bing Cheng, Dongmei Ma, Wei Shao, Wei Guo, Shuwen Wang, Ziqiao Liu, Junxiao Shen, Yiming Qi, Xuke Gong, Juan Jin, Bo Xie, Guixin Zhu, Cheng Zhang

  • January 6, 2026

Related Content

Renal clear cell carcinoma with co-existing tumor thrombosis of renal vein and ureter: a case report and review of the literature

Case Report: The revelation of a new pathogenic variant in the POT1 gene in a patient with a pediatric high-grade glioma and a renal cell carcinoma

Clinical characteristics and survival outcomes of TFE3-rearranged renal cell carcinoma: a retrospective study compared with clear cell renal cell carcinoma using propensity score matching